ATE235687T1 - Peptide mit spezifischer affinität für pacap typ 1 rezeptoren - Google Patents

Peptide mit spezifischer affinität für pacap typ 1 rezeptoren

Info

Publication number: ATE235687T1
Authority: AT; Austria
Prior art keywords: receptors; peptides; specific affinity; pacap; pacap type
Prior art date: 1996-04-25

Application number

AT97919648T

Other languages

English (en)

Inventor

Osamu Moro

Kawori Wakita

Manami Hyochi

Ethan A Lerner

Masahiro Tajima

Original Assignee

Shiseido Co Ltd

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-25

Filing date

1997-04-23

Publication date

2003-04-15

1997-04-23 Application filed by Shiseido Co Ltd, Gen Hospital Corp filed Critical Shiseido Co Ltd

2003-04-15 Application granted granted Critical

2003-04-15 Publication of ATE235687T1 publication Critical patent/ATE235687T1/de

Links

102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 title abstract 5
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 abstract 4
150000001413 amino acids Chemical class 0.000 abstract 3
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Toxicology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Bioinformatics & Computational Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT97919648T 1996-04-25 1997-04-23 Peptide mit spezifischer affinität für pacap typ 1 rezeptoren ATE235687T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/637,437 US6017533A (en)	1996-04-25	1996-04-25	Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
PCT/JP1997/001394 WO1997040388A1 (en)	1996-04-25	1997-04-23	Peptides having specific affinity to pacap type 1 receptors

Publications (1)

Publication Number	Publication Date
ATE235687T1 true ATE235687T1 (de)	2003-04-15

Family

ID=24555928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97919648T ATE235687T1 (de)	1996-04-25	1997-04-23	Peptide mit spezifischer affinität für pacap typ 1 rezeptoren

Country Status (6)

Country	Link
US (1)	US6017533A (de)
EP (1)	EP0900383B1 (de)
JP (1)	JP2000513808A (de)
AT (1)	ATE235687T1 (de)
DE (1)	DE69720207T2 (de)
WO (1)	WO1997040388A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020182729A1 (en) *	2001-01-11	2002-12-05	Dicicco-Bloom Emanuel	Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US7048934B2 (en) *	2001-08-30	2006-05-23	Stem Cell Therapeutics Inc.	Combined regulation of neural cell production
ATE541921T1 (de) *	2001-09-14	2012-02-15	Stem Cell Therapeutics Inc	Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
EP1430113A2 (de) *	2001-09-18	2004-06-23	Stem Cell Therapeutics Inc.	Wirkung von wachstumshormon und igf-1 auf neurale stammzellen und therapeutische anwendung
AU2003250705A1 (en) *	2002-07-31	2004-02-16	Stem Cell Therapeutics Inc.	Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US20050129687A1 (en) *	2003-11-03	2005-06-16	University Of Vermont And State Agricultural College	Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
JP4990634B2 (ja)	2004-02-13	2012-08-01	ステムセルセラピューティクスコーポレイション	神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用
AU2006297041A1 (en)	2005-09-27	2007-04-05	Stem Cell Therapeutics Corp.	Oligodendrocyte precursor cell proliferation regulated by prolactin
EP2004211A4 (de) *	2006-03-17	2010-07-07	Stem Cell Therapeutics Corp	Dosierschemata für lh oder hcg und epo zur behandlung von neurologischen erkrankungen
WO2009033489A2 (en) *	2007-09-11	2009-03-19	Glostrup Hospital	Selective pacl inhibitors for use in the treatment of migraine and headaches
SG11201507416WA (en)	2013-03-15	2015-10-29	Amgen Inc	Human pac1 antibodies
AU2015318008B2 (en)	2014-09-15	2021-05-20	Amgen Inc.	Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
US10822408B2 (en)	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
CN110300595A (zh)	2017-01-05	2019-10-01	加利福尼亚大学董事会	Pac1受体激动剂(maxcap)及其用途
AR111842A1 (es)	2017-06-02	2019-08-21	Amgen Inc	Antagonistas de péptido pac1
AU2019207915B2 (en)	2018-01-12	2025-09-04	Amgen Inc.	PAC1 antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5623050A (en) *	1991-08-22	1997-04-22	Takeda Chemical Industries, Ltd.	Stable polypeptides having c-AMP production enhancing activity and the use thereof
EP0618291A3 (de) *	1993-02-26	1997-12-03	Takeda Chemical Industries, Ltd.	PACAP-Rezeptor Protein, Verfahren zur dessen Herstellung und Verwendung davon
US5480864A (en) *	1993-08-06	1996-01-02	Shiseido Co., Ltd.	Modified maxadilan protein, its preparation and use, and DNA encoding the protein
KR950007873A (ko) *	1993-09-20	1995-04-15	후꾸하라 요시하루	생리 활성 물질 지속 방출형의 의약 제제
WO1996009318A1 (en) *	1994-09-22	1996-03-28	The Administrators Of The Tulane Educational Fund	Method and pharmaceutical composition for prevention and treatment of brain damage

1996
- 1996-04-25 US US08/637,437 patent/US6017533A/en not_active Expired - Fee Related
1997
- 1997-04-23 AT AT97919648T patent/ATE235687T1/de not_active IP Right Cessation
- 1997-04-23 EP EP97919648A patent/EP0900383B1/de not_active Expired - Lifetime
- 1997-04-23 DE DE69720207T patent/DE69720207T2/de not_active Expired - Fee Related
- 1997-04-23 WO PCT/JP1997/001394 patent/WO1997040388A1/en not_active Ceased
- 1997-04-23 JP JP09537926A patent/JP2000513808A/ja active Pending

Also Published As

Publication number	Publication date
JP2000513808A (ja)	2000-10-17
DE69720207T2 (de)	2003-09-25
EP0900383B1 (de)	2003-03-26
EP0900383A1 (de)	1999-03-10
US6017533A (en)	2000-01-25
WO1997040388A1 (en)	1997-10-30
DE69720207D1 (de)	2003-04-30

Legal Events

Date	Code	Title	Description
2003-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69720207D1 (de)	2003-04-30	Peptide mit spezifischer affinität für pacap typ 1 rezeptoren
NO20010284D0 (no)	2001-01-17	Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)
KR960701653A (ko)	1996-03-28	펩타이드 yy의 유사체 및 그의 용도
WO2003070747A3 (en)	2004-11-11	Insulin and igf-1 receptor agonists and antagonists
TR199902997T2 (xx)	2000-03-21	"LH-RH peptit analoglar�, bunlar�n kullan�mlar� ve bunlar� i�eren farmas�tik terkipler"
IL113617A0 (en)	1995-08-31	Soluble polypeptide fraction
NZ503850A (en)	2002-12-20	April - a novel protein with growth effects
TW343198B (en)	1998-10-21	Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
TR199901968T2 (xx)	1999-12-21	Sabit s�v� interferon form�lleri.
DE69838143D1 (de)	2007-09-06	Antimikrobielle peptide
SI1642972T1 (sl)	2010-05-31	Terapevtske uporabe BR X topnih receptorjev
WO2001072771A3 (en)	2003-12-04	Insulin and igf-1 receptor agonists and antagonists
NZ333606A (en)	2000-04-28	Isolated peptides derived from MAGE-2
ATE542138T1 (de)	2012-02-15	Her-2-bindungsantagonisten
Orloff et al.	1989	Characterization of canine renal receptors for the parathyroid hormone-like protein associated with humoral hypercalcemia of malignancy
DE69528531D1 (de)	2002-11-14	D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
ATE362939T1 (de)	2007-06-15	Dimere von thrombinpeptidderivaten
WO2001013935A3 (en)	2002-08-15	Modulation of the blood-brain barrier transporter for leptin
HUP0003396A1 (hu)	2001-02-28	Szomatosztatin antagonista peptidek
DE3751398D1 (de)	1995-08-17	Substrat-Peptide.
ATE291033T1 (de)	2005-04-15	Therapeutische peptide
AU9057791A (en)	1992-07-22	Tetrapeptide derivatives and analogues
ES2122921A1 (es)	1998-12-16	Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcino (prsv) y su empleo en diagnostico.
Kimura et al.	1982	Total synthesis of human parathyroid hormone (1–84)
PT745093E (pt)	2002-07-31	Oligopeptidos novos com afinidade para receptores opioides